Cogent Biosciences, Inc. (COGT): Cash & Equivalents
$312.01M
As of 2025-12-31
$181.17M
As of 2026-06-30
+30.7%
3-year compound annual growth
+5.2%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $312.01M | +217.8% | 2026-02-17, Balance as of period end |
| 2024-12-31 | $98.17M | +84.4% | 2026-02-17, Balance as of period end |
| 2023-12-31 | $53.23M | -61.9% | 2025-02-25, Balance as of period end |
| 2022-12-31 | $139.89M | -36.3% | 2024-02-26, Balance as of period end |
| 2021-12-31 | $219.68M | -9.3% | 2023-03-14, Balance as of period end |
| 2020-12-31 | $242.19M | +547.2% | 2022-03-15, Balance as of period end |
| 2019-12-31 | $37.42M | -32.8% | 2021-03-16, Balance as of period end |
| 2018-12-31 | $55.67M | +96.9% | 2020-03-26, Balance as of period end |
| 2017-12-31 | $28.27M | n/a | 2019-03-28, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | 2025-12-31 | $312.01M | +217.8% |
| Praxis Precision Medicines, Inc. (PRAX) | 2025-12-31 | $357.33M | +65.9% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $570.12M | -16.3% |
| Janux Therapeutics, Inc. (JANX) | 2025-12-31 | $52.33M | -87.8% |
| Xencor Inc (XNCR) | 2025-12-31 | $54.07M | +32.3% |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $296.68M | +33.3% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $120.50M | -5.6% |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $79.15M | -56.0% |
| CorMedix Inc. (CRMD) | 2025-12-31 | $144.84M | +256.3% |
Compare COGT, PRAX, BBIO, JANX side by side · Screen every company in Pharmaceutical Preparations ↗